Jia (Jenny) Liu MD PhD
@jiajennyliu.bsky.social
Early Phase Trials Medical Oncologist / Translational Researcher 👩🏻⚕️ @kinghorncancer St Vincent’s Hospital Sydney Associate Professor @UNSW. MOGA Exec. #PrecisionMedicine #drugdevelopment
Passionate about mentorship ❤️ / wellness 🤸🏻♀️/ communication 🧬📣
Passionate about mentorship ❤️ / wellness 🤸🏻♀️/ communication 🧬📣
2011 PhD student → 2025 drug development oncologist.
A long road, a lot of growth, and so many people to thank along the way.
Grateful to be promoted to Conjoint Associate Professor at @UNSW.
Excited for the next stage of global collaboration in early phase trials 🧬🧫🔬👩🏻⚕️
A long road, a lot of growth, and so many people to thank along the way.
Grateful to be promoted to Conjoint Associate Professor at @UNSW.
Excited for the next stage of global collaboration in early phase trials 🧬🧫🔬👩🏻⚕️
November 28, 2025 at 7:24 AM
2011 PhD student → 2025 drug development oncologist.
A long road, a lot of growth, and so many people to thank along the way.
Grateful to be promoted to Conjoint Associate Professor at @UNSW.
Excited for the next stage of global collaboration in early phase trials 🧬🧫🔬👩🏻⚕️
A long road, a lot of growth, and so many people to thank along the way.
Grateful to be promoted to Conjoint Associate Professor at @UNSW.
Excited for the next stage of global collaboration in early phase trials 🧬🧫🔬👩🏻⚕️
Congrats @RashaCosman on late breaking oral presentation, showcasing safety and MOA of novel in vivo CAR targeting TROP2 expressing tumors #SITC25 @NECTANSW - led trial from 🇦🇺 👏.
This technology will expand access to solid tumor cell therapy 🌟
This technology will expand access to solid tumor cell therapy 🌟
November 7, 2025 at 7:29 PM
Congrats @RashaCosman on late breaking oral presentation, showcasing safety and MOA of novel in vivo CAR targeting TROP2 expressing tumors #SITC25 @NECTANSW - led trial from 🇦🇺 👏.
This technology will expand access to solid tumor cell therapy 🌟
This technology will expand access to solid tumor cell therapy 🌟
🌏 Full circle moment — from developing my first trial protocol as a trainee at #ACORD19 to now being elected Deputy Convenor (2026) and incoming Chair of the 🇦🇺/APAC Oncology Research Workshop.
🙏 opportunity to train the next gen of clinical trialists
shorturl.at/RN44X
🙏 opportunity to train the next gen of clinical trialists
shorturl.at/RN44X
October 25, 2025 at 8:42 AM
🌏 Full circle moment — from developing my first trial protocol as a trainee at #ACORD19 to now being elected Deputy Convenor (2026) and incoming Chair of the 🇦🇺/APAC Oncology Research Workshop.
🙏 opportunity to train the next gen of clinical trialists
shorturl.at/RN44X
🙏 opportunity to train the next gen of clinical trialists
shorturl.at/RN44X
D-7 until #ESMO25! 👋🇩🇪
Excited to be part of first ever tumor-agnostic scientific track with @viveksubbiah.bsky.social @JulianaRBeale #NiamhColeman
Don’t miss these educational sessions! ⬇️ @myesmo.bsky.social
Excited to be part of first ever tumor-agnostic scientific track with @viveksubbiah.bsky.social @JulianaRBeale #NiamhColeman
Don’t miss these educational sessions! ⬇️ @myesmo.bsky.social
October 10, 2025 at 8:22 AM
D-7 until #ESMO25! 👋🇩🇪
Excited to be part of first ever tumor-agnostic scientific track with @viveksubbiah.bsky.social @JulianaRBeale #NiamhColeman
Don’t miss these educational sessions! ⬇️ @myesmo.bsky.social
Excited to be part of first ever tumor-agnostic scientific track with @viveksubbiah.bsky.social @JulianaRBeale #NiamhColeman
Don’t miss these educational sessions! ⬇️ @myesmo.bsky.social
EOI for the @MOGA_ORG Mentorship Program #NOMP25 closing soon!
We invite all 🇦🇺 med onc consultants and trainees to sign up. Benefits include networking outside your workplace, support to address career navigation, wellbeing and burnout.
🔗: shorturl.at/pS3Fg
We invite all 🇦🇺 med onc consultants and trainees to sign up. Benefits include networking outside your workplace, support to address career navigation, wellbeing and burnout.
🔗: shorturl.at/pS3Fg
September 12, 2025 at 11:06 PM
EOI for the @MOGA_ORG Mentorship Program #NOMP25 closing soon!
We invite all 🇦🇺 med onc consultants and trainees to sign up. Benefits include networking outside your workplace, support to address career navigation, wellbeing and burnout.
🔗: shorturl.at/pS3Fg
We invite all 🇦🇺 med onc consultants and trainees to sign up. Benefits include networking outside your workplace, support to address career navigation, wellbeing and burnout.
🔗: shorturl.at/pS3Fg
💡 Dendrimer may offer a non-antibody alternative to improve cytotoxic payload delivery—thanks to EPR effect in tumors
Could this be a platform for future payloads?
👏 co-authors @oncocook.bsky.social @anthonymjoshua.bsky.social #Starpharma, #ECMC + #NECTANSW 🇦🇺🇬🇧
🙏 patients, families, site teams
Could this be a platform for future payloads?
👏 co-authors @oncocook.bsky.social @anthonymjoshua.bsky.social #Starpharma, #ECMC + #NECTANSW 🇦🇺🇬🇧
🙏 patients, families, site teams
August 6, 2025 at 6:01 PM
💡 Dendrimer may offer a non-antibody alternative to improve cytotoxic payload delivery—thanks to EPR effect in tumors
Could this be a platform for future payloads?
👏 co-authors @oncocook.bsky.social @anthonymjoshua.bsky.social #Starpharma, #ECMC + #NECTANSW 🇦🇺🇬🇧
🙏 patients, families, site teams
Could this be a platform for future payloads?
👏 co-authors @oncocook.bsky.social @anthonymjoshua.bsky.social #Starpharma, #ECMC + #NECTANSW 🇦🇺🇬🇧
🙏 patients, families, site teams
Efficacy:
DCR: 56.4% (mono 3wkly), 71.4% (mono 2wkly), 81.3% (combo with 5FU)
⏳ mPFS: 2.1, 6.0, 4.2 mo respectively
🔁 Durable benefit:
• PROC: 7 pts ≥6mo (3 >12mo)
• CRC: 12 pts ≥6mo (4 >12mo)
PFS for CRC and ovarian cancer below
DCR: 56.4% (mono 3wkly), 71.4% (mono 2wkly), 81.3% (combo with 5FU)
⏳ mPFS: 2.1, 6.0, 4.2 mo respectively
🔁 Durable benefit:
• PROC: 7 pts ≥6mo (3 >12mo)
• CRC: 12 pts ≥6mo (4 >12mo)
PFS for CRC and ovarian cancer below
August 6, 2025 at 6:01 PM
Efficacy:
DCR: 56.4% (mono 3wkly), 71.4% (mono 2wkly), 81.3% (combo with 5FU)
⏳ mPFS: 2.1, 6.0, 4.2 mo respectively
🔁 Durable benefit:
• PROC: 7 pts ≥6mo (3 >12mo)
• CRC: 12 pts ≥6mo (4 >12mo)
PFS for CRC and ovarian cancer below
DCR: 56.4% (mono 3wkly), 71.4% (mono 2wkly), 81.3% (combo with 5FU)
⏳ mPFS: 2.1, 6.0, 4.2 mo respectively
🔁 Durable benefit:
• PROC: 7 pts ≥6mo (3 >12mo)
• CRC: 12 pts ≥6mo (4 >12mo)
PFS for CRC and ovarian cancer below
Safety:
✅ 89.7% of TRAEs were mild/moderate
⚠️ Neutropenia = key DLT + most common grade 3/4 event
❗️Severe GI AEs were rare (G3 diarrhea & vomiting in 0.9%, nausea in 1.8%)
🙅♀️ No cholinergic symptoms observed
✅ 89.7% of TRAEs were mild/moderate
⚠️ Neutropenia = key DLT + most common grade 3/4 event
❗️Severe GI AEs were rare (G3 diarrhea & vomiting in 0.9%, nausea in 1.8%)
🙅♀️ No cholinergic symptoms observed
August 6, 2025 at 6:01 PM
Safety:
✅ 89.7% of TRAEs were mild/moderate
⚠️ Neutropenia = key DLT + most common grade 3/4 event
❗️Severe GI AEs were rare (G3 diarrhea & vomiting in 0.9%, nausea in 1.8%)
🙅♀️ No cholinergic symptoms observed
✅ 89.7% of TRAEs were mild/moderate
⚠️ Neutropenia = key DLT + most common grade 3/4 event
❗️Severe GI AEs were rare (G3 diarrhea & vomiting in 0.9%, nausea in 1.8%)
🙅♀️ No cholinergic symptoms observed
📌 Study snapshot:
🔬 First-in-human, multi-site (🇦🇺+🇬🇧)
👥 114 patients, Tumors: CRC, ovarian, pancreatic, breast, median 4 prior lines therapy
💉 12.5 mg/m² RP2D mono and combo 5FU
🔬 First-in-human, multi-site (🇦🇺+🇬🇧)
👥 114 patients, Tumors: CRC, ovarian, pancreatic, breast, median 4 prior lines therapy
💉 12.5 mg/m² RP2D mono and combo 5FU
August 6, 2025 at 6:01 PM
📌 Study snapshot:
🔬 First-in-human, multi-site (🇦🇺+🇬🇧)
👥 114 patients, Tumors: CRC, ovarian, pancreatic, breast, median 4 prior lines therapy
💉 12.5 mg/m² RP2D mono and combo 5FU
🔬 First-in-human, multi-site (🇦🇺+🇬🇧)
👥 114 patients, Tumors: CRC, ovarian, pancreatic, breast, median 4 prior lines therapy
💉 12.5 mg/m² RP2D mono and combo 5FU
Our early-phase trial of DEP-SN38, a poly-lysine dendrimer–conjugated SN38 platform, is now published @ascocancer.bsky.social #JCO @oncocook.bsky.social
💡As TOP1I ADC programs rise, there's growing interest in better payload delivery—and not just through antibodies.
Can dendrimers assist? ⬇️🧵
💡As TOP1I ADC programs rise, there's growing interest in better payload delivery—and not just through antibodies.
Can dendrimers assist? ⬇️🧵
August 6, 2025 at 5:55 PM
Our early-phase trial of DEP-SN38, a poly-lysine dendrimer–conjugated SN38 platform, is now published @ascocancer.bsky.social #JCO @oncocook.bsky.social
💡As TOP1I ADC programs rise, there's growing interest in better payload delivery—and not just through antibodies.
Can dendrimers assist? ⬇️🧵
💡As TOP1I ADC programs rise, there's growing interest in better payload delivery—and not just through antibodies.
Can dendrimers assist? ⬇️🧵
One week until the inaugural #ESMOTATAsia25 🤩
I'm looking forward to joining global drug development experts in🍜🇭🇰
+ sharing insights on dose optimisation of novel combinations
🗓️ Saturday 19 July 2pm.
@myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social
I'm looking forward to joining global drug development experts in🍜🇭🇰
+ sharing insights on dose optimisation of novel combinations
🗓️ Saturday 19 July 2pm.
@myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social
July 11, 2025 at 7:36 PM
One week until the inaugural #ESMOTATAsia25 🤩
I'm looking forward to joining global drug development experts in🍜🇭🇰
+ sharing insights on dose optimisation of novel combinations
🗓️ Saturday 19 July 2pm.
@myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social
I'm looking forward to joining global drug development experts in🍜🇭🇰
+ sharing insights on dose optimisation of novel combinations
🗓️ Saturday 19 July 2pm.
@myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social
A powerful conclusion to the opening ceremony of #AACR25 - cancer research saves lives 💚 @theaacr.bsky.social
April 27, 2025 at 2:41 PM
A powerful conclusion to the opening ceremony of #AACR25 - cancer research saves lives 💚 @theaacr.bsky.social
Incredible #AACR25 #WICR leadership workshop on now on building resilience in science 🔬🧬💃
loving the networking and open discussions + 🥗🥪🍪
@theaacr.bsky.social @hfpconsulting.bsky.social
loving the networking and open discussions + 🥗🥪🍪
@theaacr.bsky.social @hfpconsulting.bsky.social
April 26, 2025 at 6:42 PM
Incredible #AACR25 #WICR leadership workshop on now on building resilience in science 🔬🧬💃
loving the networking and open discussions + 🥗🥪🍪
@theaacr.bsky.social @hfpconsulting.bsky.social
loving the networking and open discussions + 🥗🥪🍪
@theaacr.bsky.social @hfpconsulting.bsky.social
Link to preprint for further details ➡️ arxiv.org/abs/2409.15663
April 25, 2025 at 9:08 PM
Link to preprint for further details ➡️ arxiv.org/abs/2409.15663
Great workshop and talk #YingYuan
@mdanderson.bsky.social @fda.gov
on 🔧 backfill strategies in early phase trials including novel BARD covariate-adaptive randomisation strategies allowing dose escalation, backfill and randomisation data to ⏫ efficiency of 🧬 trials #ProjectOptimus #AACR25
@mdanderson.bsky.social @fda.gov
on 🔧 backfill strategies in early phase trials including novel BARD covariate-adaptive randomisation strategies allowing dose escalation, backfill and randomisation data to ⏫ efficiency of 🧬 trials #ProjectOptimus #AACR25
April 25, 2025 at 9:08 PM
Great workshop and talk #YingYuan
@mdanderson.bsky.social @fda.gov
on 🔧 backfill strategies in early phase trials including novel BARD covariate-adaptive randomisation strategies allowing dose escalation, backfill and randomisation data to ⏫ efficiency of 🧬 trials #ProjectOptimus #AACR25
@mdanderson.bsky.social @fda.gov
on 🔧 backfill strategies in early phase trials including novel BARD covariate-adaptive randomisation strategies allowing dose escalation, backfill and randomisation data to ⏫ efficiency of 🧬 trials #ProjectOptimus #AACR25
It’s that time of the year again… Getting ready to 🦹♀️timeshift - heading to @AACR #AACR25 and looking forward to connecting with 🌍 colleagues very soon!
April 23, 2025 at 7:57 AM
It’s that time of the year again… Getting ready to 🦹♀️timeshift - heading to @AACR #AACR25 and looking forward to connecting with 🌍 colleagues very soon!
@theaacr.bsky.social #AACR25 meeting less than 2 wks away! I’m looking forward to the clinical trials sessions in this years' meeting 'Unifying Cancer Science and Medicine: a continuum for innovation for impact' 🤝 #PatriciaLorusso
Overview of 37 oral abstracts ⬇️
Overview of 37 oral abstracts ⬇️
April 14, 2025 at 9:27 PM
@theaacr.bsky.social #AACR25 meeting less than 2 wks away! I’m looking forward to the clinical trials sessions in this years' meeting 'Unifying Cancer Science and Medicine: a continuum for innovation for impact' 🤝 #PatriciaLorusso
Overview of 37 oral abstracts ⬇️
Overview of 37 oral abstracts ⬇️
Looking forward to joining this stellar team on important webinar on #cancersurvivorship #oncsky
📅 Date: Tuesday, 27 May 2025
⏰ Time: 7:00-8:30PM (UTC+10:00) Canberra, Melbourne, Sydney
➡️ Register today - lnkd.in/gw5GJSZk
📅 Date: Tuesday, 27 May 2025
⏰ Time: 7:00-8:30PM (UTC+10:00) Canberra, Melbourne, Sydney
➡️ Register today - lnkd.in/gw5GJSZk
April 1, 2025 at 6:53 PM
Looking forward to joining this stellar team on important webinar on #cancersurvivorship #oncsky
📅 Date: Tuesday, 27 May 2025
⏰ Time: 7:00-8:30PM (UTC+10:00) Canberra, Melbourne, Sydney
➡️ Register today - lnkd.in/gw5GJSZk
📅 Date: Tuesday, 27 May 2025
⏰ Time: 7:00-8:30PM (UTC+10:00) Canberra, Melbourne, Sydney
➡️ Register today - lnkd.in/gw5GJSZk
Early ✈️ for @sahmriAU South Australian Cancer Research Network planning day representing NSW
➡️ showcasing @NECTANSW as example of successful statewide trials network to facilitate 🔬🏥🧬🧑🧑🧒🧒
Our 28 March Drug Dev Day around the corner!
Reg: oncologydrugdevelopment.weebly.com/registration...
➡️ showcasing @NECTANSW as example of successful statewide trials network to facilitate 🔬🏥🧬🧑🧑🧒🧒
Our 28 March Drug Dev Day around the corner!
Reg: oncologydrugdevelopment.weebly.com/registration...
March 16, 2025 at 6:51 PM
Early ✈️ for @sahmriAU South Australian Cancer Research Network planning day representing NSW
➡️ showcasing @NECTANSW as example of successful statewide trials network to facilitate 🔬🏥🧬🧑🧑🧒🧒
Our 28 March Drug Dev Day around the corner!
Reg: oncologydrugdevelopment.weebly.com/registration...
➡️ showcasing @NECTANSW as example of successful statewide trials network to facilitate 🔬🏥🧬🧑🧑🧒🧒
Our 28 March Drug Dev Day around the corner!
Reg: oncologydrugdevelopment.weebly.com/registration...
February 8, 2025 at 5:08 PM
Cannot think of a better candidate for AACR Board of Directors than the incredible Tim Yap - clinician scientist @mdanderson.bsky.social, drug development guru and synthetic lethality 👑.
Cast your vote @theaacr.bsky.social: www.aacr.org/professional...
#onsky #medsky #drugdevelopment
Cast your vote @theaacr.bsky.social: www.aacr.org/professional...
#onsky #medsky #drugdevelopment
January 17, 2025 at 8:09 PM
Cannot think of a better candidate for AACR Board of Directors than the incredible Tim Yap - clinician scientist @mdanderson.bsky.social, drug development guru and synthetic lethality 👑.
Cast your vote @theaacr.bsky.social: www.aacr.org/professional...
#onsky #medsky #drugdevelopment
Cast your vote @theaacr.bsky.social: www.aacr.org/professional...
#onsky #medsky #drugdevelopment
4) The real impact? Consortia can make it easier to:
➡️Find eligible patients
➡️Speed up trial activation
➡️Share expertise across borders
➡️Accelerate promising treatments
+ uniquely positioned to work with regulators, pharma & CROs to tackle evolving challenges in the field.
➡️Find eligible patients
➡️Speed up trial activation
➡️Share expertise across borders
➡️Accelerate promising treatments
+ uniquely positioned to work with regulators, pharma & CROs to tackle evolving challenges in the field.
January 15, 2025 at 5:58 PM
4) The real impact? Consortia can make it easier to:
➡️Find eligible patients
➡️Speed up trial activation
➡️Share expertise across borders
➡️Accelerate promising treatments
+ uniquely positioned to work with regulators, pharma & CROs to tackle evolving challenges in the field.
➡️Find eligible patients
➡️Speed up trial activation
➡️Share expertise across borders
➡️Accelerate promising treatments
+ uniquely positioned to work with regulators, pharma & CROs to tackle evolving challenges in the field.
3) Key roles of EPCT consortia:
🌟Facilitating collaborative research
🌟Running MTBs
🌟Matching patients to biomarker-driven Rx
🌟Streamlining operations and ensuring these are patient-centric e.g. decentralised
🌟Improving cost-efficiency
🌟 Mentor+support new investigators
🌟Facilitating collaborative research
🌟Running MTBs
🌟Matching patients to biomarker-driven Rx
🌟Streamlining operations and ensuring these are patient-centric e.g. decentralised
🌟Improving cost-efficiency
🌟 Mentor+support new investigators
January 15, 2025 at 5:58 PM
3) Key roles of EPCT consortia:
🌟Facilitating collaborative research
🌟Running MTBs
🌟Matching patients to biomarker-driven Rx
🌟Streamlining operations and ensuring these are patient-centric e.g. decentralised
🌟Improving cost-efficiency
🌟 Mentor+support new investigators
🌟Facilitating collaborative research
🌟Running MTBs
🌟Matching patients to biomarker-driven Rx
🌟Streamlining operations and ensuring these are patient-centric e.g. decentralised
🌟Improving cost-efficiency
🌟 Mentor+support new investigators
2) Our review identified 15 major EPCT consortia globally:
2 in USA
3 in Europe
5 in Asia-Pacific 🌏
2 intercontinental
3 private networks
These consortia span different funding models including government-funded, charity/academia-supported and private research organizations
2 in USA
3 in Europe
5 in Asia-Pacific 🌏
2 intercontinental
3 private networks
These consortia span different funding models including government-funded, charity/academia-supported and private research organizations
January 15, 2025 at 5:58 PM
2) Our review identified 15 major EPCT consortia globally:
2 in USA
3 in Europe
5 in Asia-Pacific 🌏
2 intercontinental
3 private networks
These consortia span different funding models including government-funded, charity/academia-supported and private research organizations
2 in USA
3 in Europe
5 in Asia-Pacific 🌏
2 intercontinental
3 private networks
These consortia span different funding models including government-funded, charity/academia-supported and private research organizations
Oncology drug development 🧬💊 has come a long way, but the system is riddled with inefficiency, inequity and costs are ⏫.
Excited to share our 🌎 review article in press in JCO
@ascocancer.bsky.social
highlighting role of early phase consortia in tackling these challenges: 🧵 1)
#medsky #oncsky
Excited to share our 🌎 review article in press in JCO
@ascocancer.bsky.social
highlighting role of early phase consortia in tackling these challenges: 🧵 1)
#medsky #oncsky
January 15, 2025 at 5:58 PM
Oncology drug development 🧬💊 has come a long way, but the system is riddled with inefficiency, inequity and costs are ⏫.
Excited to share our 🌎 review article in press in JCO
@ascocancer.bsky.social
highlighting role of early phase consortia in tackling these challenges: 🧵 1)
#medsky #oncsky
Excited to share our 🌎 review article in press in JCO
@ascocancer.bsky.social
highlighting role of early phase consortia in tackling these challenges: 🧵 1)
#medsky #oncsky